;PMID: 1391809
;source_file_1421.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..134] = [t:39..134]
;2)section:[e:138..211] = [t:138..211]
;3)section:[e:215..290] = [t:215..290]
;4)sentence:[e:294..481] = [t:294..481]
;5)sentence:[e:482..578] = [t:482..578]
;6)sentence:[e:579..766] = [t:579..766]
;7)sentence:[e:767..913] = [t:767..913]
;8)sentence:[e:914..1136] = [t:914..1136]
;9)sentence:[e:1137..1228] = [t:1137..1228]
;10)sentence:[e:1229..1340] = [t:1229..1340]
;11)section:[e:1344..1388] = [t:1344..1388]

;section 0 Span:0..34
;Int J Hematol  1992 Aug;56(1):9-15
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..13] Hematol) (CD:[15..19] 1992)
        (CD:[20..27] Aug;56-LRB-) (CD:[27..28] 1) (-RRB-:[28..29] -RRB-)
        (CD:[29..31] :9) (IN:[31..32] -) (CD:[32..34] 15)))

;sentence 1 Span:39..134
;N-RAS activation in the terminal stage of undifferentiated chronic 
;myeloproliferative disease.
;[39..44]:gene-rna:"N-RAS"
;[81..133]:malignancy:"undifferentiated chronic  myeloproliferative disease"
(SENT
  (NP-HLN
    (NP (NN:[39..44] N-RAS) (NN:[45..55] activation))
    (PP (IN:[56..58] in)
      (NP (DT:[59..62] the) (JJ:[63..71] terminal) (NN:[72..77] stage)))
    (PP (IN:[78..80] of)
      (NP (JJ:[81..97] undifferentiated) (JJ:[98..105] chronic)
          (JJ:[107..125] myeloproliferative) (NN:[126..133] disease)))
    (.:[133..134] .)))

;section 2 Span:138..211
;Inokuchi K, Futaki M, Miyake K, Kuwabara T, Shinohara T, Dan K, Nomura T.
(SEC
  (FRAG (NNP:[138..146] Inokuchi) (NNP:[147..148] K) (,:[148..149] ,)
        (NNP:[150..156] Futaki) (NNP:[157..159] M,) (NNP:[160..166] Miyake)
        (NNP:[167..168] K) (VBD:[168..169] ,) (NNP:[170..178] Kuwabara)
        (NNP:[179..180] T) (VBD:[180..181] ,) (NNP:[182..191] Shinohara)
        (NNP:[192..193] T) (,:[193..194] ,) (NNP:[195..198] Dan)
        (NNP:[199..200] K) (,:[200..201] ,) (NNP:[202..208] Nomura)
        (NNP:[209..211] T.)))

;section 3 Span:215..290
;Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
(SEC
  (FRAG (NNP:[215..220] Third) (NNP:[221..231] Department) (IN:[232..234] of)
        (NNP:[235..243] Internal) (NNP:[244..252] Medicine) (,:[252..253] ,)
        (NNP:[254..260] Nippon) (NNP:[261..268] Medical) (NNP:[269..275] School)
        (,:[275..276] ,) (NNP:[277..282] Tokyo) (,:[282..283] ,)
        (NNP:[284..289] Japan) (.:[289..290] .)))

;sentence 4 Span:294..481
;The relationship between activation of the N-RAS gene and the leukemic 
;progression of undifferentiated chronic myeloproliferative disease (UCMPD)
;was  investigated in a 71-year-old male.
;[337..342]:gene-rna:"N-RAS"
;[381..432]:malignancy:"undifferentiated chronic myeloproliferative disease"
;[434..439]:malignancy:"UCMPD"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[294..297] The) (NN:[298..310] relationship))
      (PP (IN:[311..318] between)
        (NP
          (NP
            (NP (NN:[319..329] activation))
            (PP (IN:[330..332] of)
              (NP (DT:[333..336] the) (NN:[337..342] N-RAS) (NN:[343..347] gene))))
          (CC:[348..351] and)
          (NP
            (NP (DT:[352..355] the) (JJ:[356..364] leukemic)
                (NN:[366..377] progression))
            (PP (IN:[378..380] of)
              (NP
                (NP (JJ:[381..397] undifferentiated) (JJ:[398..405] chronic)
                    (JJ:[406..424] myeloproliferative) (NN:[425..432] disease))
                (NP (-LRB-:[433..434] -LRB-) (NN:[434..439] UCMPD)
                    (-RRB-:[439..440] -RRB-))))))))
    (VP (VBD:[441..444] was)
      (VP (VBN:[446..458] investigated)
        (NP-1 (-NONE-:[458..458] *))
        (PP-LOC (IN:[459..461] in)
          (NP (DT:[462..463] a)
            (ADJP
              (NML (CD:[464..466] 71) (HYPH:[466..467] -) (NN:[467..471] year))
              (HYPH:[471..472] -) (JJ:[472..475] old))
            (NN:[476..480] male)))))
    (.:[480..481] .)))

;sentence 5 Span:482..578
;Hematologically, it was difficult to  differentiate the UCMPD from chronic
;myelogenous leukemia.
;[538..543]:malignancy:"UCMPD"
;[549..577]:malignancy:"chronic myelogenous leukemia"
(SENT
  (S
    (ADVP (RB:[482..497] Hematologically))
    (,:[497..498] ,)
    (NP-SBJ (PRP:[499..501] it))
    (VP (VBD:[502..505] was)
      (ADJP-PRD (JJ:[506..515] difficult)
        (S-ADV
          (NP-SBJ (-NONE-:[515..515] *))
          (VP (TO:[516..518] to)
            (VP (VB:[520..533] differentiate)
              (NP (DT:[534..537] the) (NN:[538..543] UCMPD))
              (PP (IN:[544..548] from)
                (NP (JJ:[549..556] chronic) (JJ:[557..568] myelogenous)
                    (NN:[569..577] leukemia))))))))
    (.:[577..578] .)))

;sentence 6 Span:579..766
;Chromosomal analysis  revealed no Philadelphia chromosome (Ph1-), and DNA
;analysis revealed no BCR  rearrangement (BCR-) either at the beginning or in
;the terminal stages of the  disease.
;[613..636]:variation-event:"Philadelphia chromosome"
;[638..642]:variation-event:"Ph1-"
;[674..692]:variation-event:"BCR  rearrangement"
;[674..677]:gene-rna:"BCR"
;[694..698]:variation-event:"BCR-"
;[694..697]:gene-rna:"BCR"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[579..590] Chromosomal) (NN:[591..599] analysis))
      (VP (VBD:[601..609] revealed)
        (NP
          (NP (DT:[610..612] no)
             (NNP:[613..625] Philadelphia) (NN:[626..636] chromosome))
          (NP (-LRB-:[637..638] -LRB-)
             (NN:[638..641] Ph1) (SYM:[641..642] -)
            (-RRB-:[642..643] -RRB-)))))
    (,:[643..644] ,) (CC:[645..648] and)
    (S
      (NP-SBJ (NN:[649..652] DNA) (NN:[653..661] analysis))
      (VP (VBD:[662..670] revealed)
        (NP
          (NP (DT:[671..673] no)
             (NN:[674..677] BCR) (NN:[679..692] rearrangement))
          (NP (-LRB-:[693..694] -LRB-)
             (NN:[694..697] BCR) (SYM:[697..698] -)
            (-RRB-:[698..699] -RRB-)))
        (PP (CC:[700..706] either)
          (PP (IN:[707..709] at)
            (NP (DT:[710..713] the) (NN:[714..723] beginning))
            (PP-1 (-NONE-:[723..723] *RNR*)))
          (CC:[724..726] or)
          (PP (IN:[727..729] in)
            (NP
              (NP (DT:[730..733] the) (JJ:[734..742] terminal)
                  (NNS:[743..749] stages))
              (PP-1 (-NONE-:[749..749] *RNR*))))
          (PP-1 (IN:[750..752] of)
            (NP (DT:[753..756] the) (NN:[758..765] disease))))))
    (.:[765..766] .)))

;sentence 7 Span:767..913
;We performed a tumorigenicity assay, using NIH3T3 cells, and molecular 
;analysis, using the polymerase chain reaction (PCR) and direct sequencing.
;[859..869]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ (PRP:[767..769] We))
    (VP
      (VP (VBD:[770..779] performed)
        (NP=1 (DT:[780..781] a) (NN:[782..796] tumorigenicity)
              (NN:[797..802] assay))
        (,:[802..803] ,)
        (S-MNR=2
          (NP-SBJ (-NONE-:[803..803] *))
          (VP (VBG:[804..809] using)
            (NP (NN:[810..816] NIH3T3) (NNS:[817..822] cells)))))
      (,:[822..823] ,) (CC:[824..827] and)
      (VP
        (NP=1 (JJ:[828..837] molecular) (NN:[839..847] analysis))
        (,:[847..848] ,)
        (S-MNR=2
          (NP-SBJ (-NONE-:[848..848] *))
          (VP (VBG:[849..854] using)
            (NP
              (NP
                (NP (DT:[855..858] the) (NN:[859..869] polymerase)
                    (NN:[870..875] chain) (NN:[876..884] reaction))
                (NP (-LRB-:[885..886] -LRB-) (NN:[886..889] PCR)
                    (-RRB-:[889..890] -RRB-)))
              (CC:[891..894] and)
              (NP (JJ:[895..901] direct) (NN:[902..912] sequencing)))))))
    (.:[912..913] .)))

;sentence 8 Span:914..1136
;The  DNA of leukemic cells at the beginning of the leukemic progression did
;not show  any abnormalities, but at the terminal stage of the disease the DNA
;showed a  point mutation in codon 12 (GGT----GCT) of the N-RAS gene.
;[926..940]:malignancy:"leukemic cells"
;[1030..1059]:malignancy:"terminal stage of the disease"
;[1078..1092]:variation-type:"point mutation"
;[1096..1104]:variation-location:"codon 12"
;[1106..1109]:variation-state-original:"GGT"
;[1113..1116]:variation-state-altered:"GCT"
;[1125..1130]:gene-rna:"N-RAS"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[914..917] The) (NN:[919..922] DNA))
        (PP (IN:[923..925] of)
          (NP
            (NP (JJ:[926..934] leukemic) (NNS:[935..940] cells))
            (PP-TMP (IN:[941..943] at)
              (NP
                (NP (DT:[944..947] the) (NN:[948..957] beginning))
                (PP (IN:[958..960] of)
                  (NP (DT:[961..964] the) (JJ:[965..973] leukemic)
                      (NN:[974..985] progression))))))))
      (VP (VBD:[986..989] did) (RB:[990..993] not)
        (VP (VB:[994..998] show)
          (NP (DT:[1000..1003] any) (NNS:[1004..1017] abnormalities)))))
    (,:[1017..1018] ,) (CC:[1019..1022] but)
    (S
      (PP-TMP (IN:[1023..1025] at)
        (NP
          (NP (DT:[1026..1029] the) (JJ:[1030..1038] terminal)
              (NN:[1039..1044] stage))
          (PP (IN:[1045..1047] of)
            (NP (DT:[1048..1051] the) (NN:[1052..1059] disease)))))
      (NP-SBJ (DT:[1060..1063] the) (NN:[1064..1067] DNA))
      (VP (VBD:[1068..1074] showed)
        (NP
          (NP (DT:[1075..1076] a)
             (NN:[1078..1083] point) (NN:[1084..1092] mutation))
          (PP-LOC (IN:[1093..1095] in)
            (NP
              (NP (NN:[1096..1101] codon) (CD:[1102..1104] 12))
              (PRN (-LRB-:[1105..1106] -LRB-)
                (NP
                  (NP (NN:[1106..1109] GGT))
                  (PP (SYM:[1109..1113] ----)
                    (NP (NN:[1113..1116] GCT))))
                (-RRB-:[1116..1117] -RRB-))
              (PP (IN:[1118..1120] of)
                (NP (DT:[1121..1124] the) (NN:[1125..1130] N-RAS)
                    (NN:[1131..1135] gene))))))))
    (.:[1135..1136] .)))

;sentence 9 Span:1137..1228
;Interestingly, a  codon 13 mutation (GGT----GTT) was also detected by
;tumorigenicity assay.
;[1155..1163]:variation-location:"codon 13"
;[1164..1172]:variation-event:"mutation"
;[1174..1177]:variation-state-original:"GGT"
;[1181..1184]:variation-state-altered:"GTT"
(SENT
  (S
    (ADVP (RB:[1137..1150] Interestingly))
    (,:[1150..1151] ,)
    (NP-SBJ-1 (DT:[1152..1153] a)
      (NML (NN:[1155..1160] codon) (CD:[1161..1163] 13))
      (NN:[1164..1172] mutation)
      (PRN (-LRB-:[1173..1174] -LRB-)
        (NP
          (NP (NN:[1174..1177] GGT))
          (PP (SYM:[1177..1181] ----)
            (NP (NN:[1181..1184] GTT))))
        (-RRB-:[1184..1185] -RRB-)))
    (VP (VBD:[1186..1189] was)
      (ADVP (RB:[1190..1194] also))
      (VP (VBN:[1195..1203] detected)
        (NP-1 (-NONE-:[1203..1203] *))
        (PP-MNR (IN:[1204..1206] by)
          (NP (NN:[1207..1221] tumorigenicity) (NN:[1222..1227] assay)))))
    (.:[1227..1228] .)))

;sentence 10 Span:1229..1340
;These  observations suggest that the activated N-RAS gene contributes to the 
;hematologic progression of UCMPD.
;[1276..1281]:gene-rna:"N-RAS"
;[1334..1339]:malignancy:"UCMPD"
(SENT
  (S
    (NP-SBJ (DT:[1229..1234] These) (NNS:[1236..1248] observations))
    (VP (VBP:[1249..1256] suggest)
      (SBAR (IN:[1257..1261] that)
        (S
          (NP-SBJ (DT:[1262..1265] the) (VBN:[1266..1275] activated)
                  (NN:[1276..1281] N-RAS) (NN:[1282..1286] gene))
          (VP (VBZ:[1287..1298] contributes)
            (PP-CLR (TO:[1299..1301] to)
              (NP
                (NP (DT:[1302..1305] the) (JJ:[1307..1318] hematologic)
                    (NN:[1319..1330] progression))
                (PP (IN:[1331..1333] of)
                  (NP (NN:[1334..1339] UCMPD)))))))))
    (.:[1339..1340] .)))

;section 11 Span:1344..1388
;PMID: 1391809 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1344..1348] PMID) (::[1348..1349] :) (CD:[1350..1357] 1391809)
        (IN:[1358..1359] -LSB-) (NNP:[1359..1365] PubMed) (HYPH:[1366..1367] -)
        (JJ:[1368..1375] indexed) (IN:[1376..1379] for)
        (NNP:[1380..1388] MEDLINE-RSB-)))
